Pharmacogenetic aspects of neuroleptic malignant syndrome

Current Pharmacogenomics

Volumn 4, Issue 2, 2006, Pages 113-119

  Kawanishi, Chiaki ^a,b   Kishida, Ikuko ^a,b   Furuno, Taku ^a,b   Kato, Daiji ^a,b   Bertilsson, Leif ^a,b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytochrome P450 2D6; Dopamine D2 receptor; Genetic polymorphisms; Neuroleptic malignant syndrome

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; NEUROLEPTIC AGENT;

ALLELE; ARTICLE; AUTONOMIC DYSFUNCTION; CASE CONTROL STUDY; CONSCIOUSNESS DISORDER; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG FATALITY; EXTRAPYRAMIDAL SYMPTOM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HEREDITY; HUMAN; HYPERTHERMIA; INCIDENCE; MOLECULAR GENETICS; NEUROLEPTIC MALIGNANT SYNDROME; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTION; PSYCHOPHARMACOTHERAPY; RISK FACTOR; SYMPTOM;

EID: 33744811750     PISSN: 15701603     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016006776286891     Document Type: Article

References (81)

1. Adityanjee; Mathews, T. and Aderibigbe, Y. A. (1999a) Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int. J. Neuropsychopharmacol. 2, 129-144.
2. Adityanjee; Aderibigbe, Y. A. and Mathews, T. (1999b) Epidemiology of neuroleptic malignant syndrome. Clin. Neuropharmacol. 22, 151-158.
3. Addonizio, G.; Susman, V. L. and Roth, S. D. (1987) Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol. Psychiatry 22, 1004-1020.
4. Adnet, P. J.; Krivosic-Horber, R. M.; Adamantidis, M. M.; Haudecoeur, G.; Adnet-Bonte, C. A.; Saulnier, F. and Dupuis, B. A. (1989) The association between the neuroleptic malignant syndrome and malignant hyperthermia. Acta Anaesthesiol. Scand. 33, 676-680.
5. Ananth, J.; Parameswaren, S.; Gunatilake, S.; Burgoyne, K. and Sidhom, T. (2004) Neuroleptic malignant syndrome and atypical antipsychotic drugs. J. Clin. Psychiatry 65, 464-470.
6. Andreassen, O. A.; MacEvan, T.; Gulbrandsen, A. K.; McCreadie, R. G. and Steen, V. M. (1997) Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacol. 131, 174-179.
7. Arinami, T.; Gao, M.; Hamaguchi, H. and Toru, M. (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. 6, 577-582.
8. Ayd, F. J. (1956) Fatal hyperpyrexia during chlorpromazine therapy. J. Clin. Exp. Psychopath. 17, 189.
9. Basile, V. S.; Masellis, M.; Badri, F.; Paterson, A. D.; Meltzer, H. Y.; Lieberman, J. A.; Potkin, S. G.; Macciardi, F. and Kennedy, J. L. (1999) Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacol. 21, 17-27.
10. Berardi, D.; Amore, M.; Keck, P. E. Jr.; Troia, M. and Dell'Atti, M. (1998) Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol. Psychiatry 44, 748-754.
11. Bertilsson, L.; Dahl, M.-L.; Dalén, P. and Al-Shurbaji, S. (2002) Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53, 111-122.
12. Caroff, S. N. and Mann, S. C. (1988) Neuroleptic Malignant Syndrome. Psychopharmacol. Bull. 24, 25-29.
13. Caroff, S. N. and Mann, S. C. (1993) Neuroleptic malignant syndrome. Med. Clin. North Am. 77, 185-202.
14. Caroff, S. N.; Mann, S. C. and Campbell, E. C. (2000) Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Ann. 30, 314-321.
15. Cravchik, A.; Sibley, D. R. and Gejman, P. V. (1999) Analysis of neuroleptic binding affinities and potencies for the human dopamine D2 receptor missense variants. Pharmacogenet. 9, 17-23.
16. Dalén, P.; Dahl, M.-L.; Ruiz, M. L. B.; Nordin, J. and Bertilsson, L. (1998) 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther. 63, 444-452.
17. Delay, J.; Pichot, P.; Lemperiere, T.; Elissalde, B. and Peigne, F. (1960) Un neuroleptique majeur non phenothiazinique et non reserpinique, l'haloperidol, dans le traitement des psychoses. Ann. Med. Psychol. 18, 145-152.
18. Delay, J. and Deniker, P. (1968) Drug-induced extrapyramidal syndrome. In Handbook of Clinical Neurology; Vinken, P.J. and Bruyn, G.W.; Eds.; North-Holland Publishing Company: Amsterdam, pp. 248-266.
19. Dettling, M. and Cascorbi, I. (2001) Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-Jewish Caucasian sample. Arch. Gen. Psychiatry 58, 93-94.
20. Deuschl, G.; Oepen, G. and Hermle, L. (1987) Neuroleptic malignant syndrome: Observations on altered consciousness. Pharmacopsychiatry 20, 168-170.
21. Eichelbaum, M.; Fromm, M. F. and Schwab, M. (2004) Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 26, 180-185.
22. Eichhammer, P.; Albus, M.; Borrmann-Hasseenbach, M.; Schoeler, A.; Putzhammer, A., Frick, U.; Klein, H. E. and Rohrmeier, T. (2000) Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. Am. J. Med. Genet. 96, 187-191.
23. Ellingrod, V.; Perry, P.; Ringold, J.; Lund, B.; Bever-Stille, K.; Fleming, F.; Holman, T. L. and Miller, D. (2005) Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am. J. Med. Genet. 134B, 76-78.
24. Ingelman-Sundberg, M. (2001) Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Int. Med. 250, 186-200.
25. Itoh, H.; Ohtsuka, N.; Ogita, K.; Yagi, G.; Miura, S. and Koga, Y. (1977) Malignant neuroleptic syndrome: its present status in Japan and clinical problems. Folia Psychiatr. Neurol. Jpn. 31, 565-576.
26. Iwahashi, K.; Yoshihara, E.; Nakamura, K.; Ameno, K.; Watanabe, M.; Tsuneoka, Y.; Ichikawa, Y. and Igarashi, K. (1999) CYP2D6 HhaI genotype and the neuroleptic malignant syndrome. Neuropsychobiol. 39, 33-37.
27. 123I]Iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome. Mov. Dis. 11, 726-726.
28. Jönsson, E. G.; Nöthen, M. M.; Grünhage, F.; Farde, L.; Nakashima, Y.; Propping, P., et al.: (1999) Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 4, 290-296.
29. Kapitany, T.; Meszaros, K.; Lenzinger, E.; Schindler, S. D.; Barnas, C.; Fuchs, K.; Sieghart, W.; Aschauer, H. N. and Kasper, S. (1998) Genetic polymorphisms for drug metabolism and tardive dyskinesia in schizophrenia. Schizophrenia Res. 32, 101-106.
30. Kawanishi, C.; Hanihara, T.; Maruyama, Y.; Matsumura, T.; Onishi, H.; Inoue, K.; Sugiyama, N.; Suzuki, K.; Yamada, Y. and Kosaka, K. (1997) Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B. Psychiatric Genet. 7, 127-129.
31. Kawanishi, C.; Shimoda, Y.; Fujimaki, J.; Onishi, H.; Suzuki, K.; Hanihara, T.; Sugiyama, N. and Kosaka, K. (1998a) Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. J. Neurol. Sci. 160, 102-104.
32. Kawanishi, C.; Hanihara, T.; Shimoda, Y.; Suzuki, K.; Sugiyama, N.; Onishi, H.; Moyakawa, T.; Yamada, Y. and Kosaka, K. (1998b) Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HT1A and 5-HT2A receptor genes. Am. J. Psychiatry 155, 1275-1277.
33. Kawanishi, C.; Furuno, T.; Onishi, H.; Sugiyama, N.; Suzuki, K.; Matsumura, T.; Ishigami, T. and Kosaka, K. (2000) Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiatric Genet. 10, 145-147.
34. Kawanishi, C.; Onishi, H.; Kato, D.; Yamada, T.; Onose, M.; and Hirayasu, Y. (2005) Neuroleptic malignant syndrome in cancer treatment. Palliat Support Care, 3, 51-53.
35. Keck, P. E. Jr.; Pope, H. G. Jr.; Cohen, B. M.; McElroy, S. L. and Nierenberger, A. A. (1989) Risk factors for neuroleptic malignant syndrome: A case-control study. Arch. Gen. Psychiatry 46, 914-918.
36. Kishida, I.; Kawanishi, C.; Furuno, T.; Matsumura, T.; Hasegawa, H.; Sugiyama, N.; Suzuki, K.; Yamada, Y. and Kosaka, K. (2003) Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene. Psychiatric Genet. 13, 55-57.
37. Kishida, I.; Kawanishi, C.; Furuno, T.; Kato, D.; Ishigami, T. and Kosaka, K. (2004) Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D2 receptor gene. Mol. Psychiatry 9, 293-298.
38. Kishida, I.; Kawanishi, C.; Furuno, T.; Kato, D. and Hirayasu, Y. (2004) Investigating the association between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D2 and D3 receptor gene. Eur. Neuropsychopharmacol. 14, S244.
39. Kontaxakis, V. P.; Christodoulou, G. N.; Markidis, M. P. and Havaki-Kontaxaki, B. J. (1998) Treatment of a mild form of neuroleptic malignant syndrome with oral diazepam. Acta Psychiatr. Scand. 78, 396-398.
40. Lazarus, A. L.; Moore, K. E. and Spinner, N. B. (1991) Recurrent neuroleptic malignant syndrome associated with inv dup (15) and mental retardation. Clin. Genet. 39, 65-67.
41. Leucht, S.; Pitschel-Walz, G.; Abraham, D. and Kissling, W. (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotic and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 35, 51-68.
42. LLerena, A.; Alm, C.; Dahl, M.-L.; Ekqvist, B. and Bertilsson, L. (1992) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther. Drug Monit. 14, 92-97.
43. Lundstrom, K. and Turpin, M. P. (1996) Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem. Biophys. Res. Commun. 225, 1068-1072.
44. Mahendran, R.; Winslow, M. and Lim, D. (2000) Recurrent neuroleptic malignant syndrome. Aust. NZ. J. Psychiatry. 34, 699-700.
45. Manor, I.; Hermesh, H.; Munitz, H. and Weizman, A. (1997) Neuroleptic malignant syndrome with gangliosidosis type II. Biol. Psychiatry 41, 1222-1224.
46. Matsumoto, T.; Kawanishi, C.; Isojima, D.; Iseki, E.; Kishida, I. and Kosaka, K. (2004) Neuroleptic malignant syndrome induced by donepezil. Int. J. Neuropsychopharmacol. 7, 101-103.
47. Meyer, U. A. (2000) Pharmacogenetics and adverse drug reactions. Lancet. 356, 1667-1671.
48. Mihara, K.; Kondo, T.; Suzuki, A.; Yasui, N.; Furukori, H.; Nagashima, U.; Ono, S.; Kaneko, S.; Otani, K. and Inoue, Y. (2000) Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene. Psychopharmacol. 149, 246-250.
49. Mihara, K.; Suzuki, A.; Kondo, T.; Yasui-Furukori, N.; Ono, S.; Otani, K.; Kaneko, S.; and Inoue, Y. (2001) Relationship between Taq1A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am. J. Med. Genet. 105, 271-274.
50. Mihara, K.; Kondo, T.; Suzuki, A.; Yaui-Furukori, N.; Ono, S.; Sano, A.; Koshiro, K.; Otani, K. and Kaneko, S. (2003) Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am. J. Med. Genet. 117B, 57-60.
51. Miyatake, R.; Iwahashi, K.; Matsushita, M.; Nakamura, K. and Suwaki, H. (1996) No association between the neuroleptic malignant syndrome and mutations in the RYR 1 gene associated malignant hyperthermia. J. Neurol. Sci. 143, 161-165.
52. Miyaoka, H.; Shishikura, K.; Otsubo, T.; Muramatsu, D. and Kamijima, K. (1997) Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype? Am. J. Psychiatry 154, 882.
53. McCarthy, T. V.; Quane, K. A. and Lynch, P. J. (2000) Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum. Mutat. 15, 410-417.
54. Nemecek, D.; Rastogi-Cruz, D. and Csernansky, J. G. (1993) Atropinism may precipitate neuroleptic malignant syndrome during treatment of clozapine. Am. J. Psychiatry 150, 1561.
55. Nishijima, K. and Ishiguro, T. (1990) Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. Biol. Psychiatry 27, 280-288.
56. 2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. Alcohol. 16, 33-45.
57. Nyberg, S.; Dahl, M.-L. and Halldin, C. (1995) A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquine and risperidone. Psychopharmacol. 119, 345-348.
58. Ohmori, O.; Suzuki, T.; Kojima, H.; Shinkai, T.; Terao, T.; Mita, T. and Abe K. (1998) Tardive dyskinesia and debrisoquine 4-hydroxylase genotype in Japanese schizophrenics. Schizophrenia Res. 32, 107-113.
59. Onose, M.; Kawanishi, C.; Onishi, H.; Yamada, T.; Itoh, M.; Kosaka, K.; Taguchi, J.; Fujisawa, S. and Kanamori, H. (2002) Neuroleptic malignant syndrome following bone marrow transplantation. Bone Marrow Transplant. 29, 803-804.
60. Otani, K.; Horiuchi, M.; Kondo, T.; Kaneko, S. and Fukushima, Y. (1991) Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br. J. Psychiatry 158, 850-853.
61. Pacifici, G. M. and Pelkonen, O.; Eds. (2001) Interindividual variability in drug metabolism in humans. Taylor & Francis: London.
62. Pohjalainen, T.; Rinne, J.O.; Någren, K.; Lehikoinen, P.; Anttila, K.; Syvälahti, E. K. G. and Hietala, J. (1998) The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 3, 256-260.
63. 2 receptor density in vivo. Pharmacogenet. 9, 505-509.
64. Pope, G. H.; Keck, P. E. and McElroy, S. L. (1986) Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am. J. Psychiatry 143, 1227-1233.
65. Ram, A.; Cao, Q.; Keck, P. E. Jr.; Pope, H.G. Jr.; Otani, K.; Addonizio, G.; McElroy, S. L.; Kaneko, S.; Redlichova, M.; Gershon, E. S. and Gejman, P. V. (1995) Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome. Am. J. Med. Genet. 60, 228-230.
66. Reynolds, G. P.; Zhang, Z. and Zhang X. (2003) Polymorphism of the promoter region of the serotonin 5-HT2C receptor gene and clozapine-induced weight gain. Am. J. Psychiatry 160, 677-679.
67. Russell, C. S.; Lang, C.; McCambridge, M. and Calhoun, B. (2001) Neuroleptic malignant syndrome in pregnancy. Obstet. Gynecol. 98, 906-908.
68. Sachdev, P.; Mason, C. and Hadzi-Pavlovic, D. (1997) Case-control study of neuroleptic malignant syndrome. Am. J. Psychiatry 154, 1156-1158.
69. Schäfer, M.; Rujescu, D.; Giegling, I.; Guntermann, A.; Erfurth, A.; Bondy, B. and Möller H.J. (2001) Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene. Am. J. Psychiatry 158, 802-804.
70. Scordo, M. G. and Spina, E. (2002) Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenom. 3, 201-218.
71. Segman, R. H.; Heresco-Levy, U.; Finkel, B.; Inbar, R.; Neeman, T.; Schlafman, M.; Dorevitch, A.; Yakir, A.; Goltser, T.; Shelevoy, A. and Lerer, B. (2000) Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacol. 152, 408-413.
72. Shalev, A. and Munitz, H. (1986) The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr. Scand. 73, 337-347.
73. Shalev, A.; Hermesh, H. and Munitz, H. (1989) Mortality from neuroleptic malignant syndrome. J. Clin. Psychiatry 50, 18-25.
74. Sokoloff, P.; Giros, B.; Martres, M. P.; Bouthenet, M. L. and Schwartz, J. C. (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347, 146-151.
75. Suzuki, A.; Kondo, T.; Otani, K.; Mihara, K.; Yasui-Furukori, N.; Sano, A., Koshiro, K. and Kaneko, S. (2001) Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. Am. J. Psychiatry. 158, 1714-1716.
76. Tanaka, K.; Akechi, T.; Yamazaki, M.; Hayashi, R.; Nishiwaki, Y. and Uchitomi, Y. (1998) Neuroleptic malignant syndrome during haloperidol treatment in a cancer patient: a case report. Support. Care Cancer. 6, 536-538.
77. Tanaka, S.; Matsunaga, H.; Kimura, M.; Tatsumi, K.; Hidaka, Y.; Takano, T.; Uema, T.; Takeda, M. and Amino, N. (1996) Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J. Neuroimmunol. 141, 155-164.
78. Thompson, J.; Thomas, N.; Singleton, A.; Piggott, M.; Lloyd, S.; Perry, E. K.; Morris, C. M.; Perry, R. H.; Ferrier, I. N. and Court, J. A. (1997) D2 dopamine receptor gene (DRD2) TaqI A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenet. 7, 479-484.
79. Wappler, F. (2001) Malignant hyperthermia. Eur. J. Anaesthesiol. 18, 632-652.
80. Wells, A. J.; Sommi, R. W. and Crismon, L. (1988) Neuroleptic malignant syndrome: case report and literature review. Drug Intell. Clin. Pharmacol. 22, 475-480.
81. Yano, E. and Yamawaki, S. (1989) Epidemiology of neuroleptic malignant syndrome in Japan. Jp. J. Clin. Psychiatry. 18, 465-471.